Key Highlights

  • Contineum Therapeutics' Johnson & Johnson-partnered asset, JNJ-5120/PIPE-307, missed its primary endpoint in the Phase 2 MOONLIGHT-1 study.
  • The study targeted major depressive disorder.
  • The compound failed to show a statistically significant MADRS total score reduction against placebo at Day 5.
  • The compound was well tolerated, with zero novel safety concerns.

Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported that its Johnson & Johnson-partnered asset, JNJ-5120/PIPE-307, missed its primary endpoint within the Phase 2 MOONLIGHT-1 major depressive disorder study, failing to show a statistically significant MADRS total score reduction against placebo at Day 5.

What Happened

Though the compound was well tolerated with zero novel safety concerns, exploratory evaluation continues to guide future development.

Market Reaction

The disclosed information does not include stock price or trading data for Contineum Therapeutics following the MOONLIGHT-1 results.

Outlook

Continued exploratory evaluation of JNJ-5120/PIPE-307 following the MOONLIGHT-1 miss represents the next relevant step in guiding the program's future development path.